重组人表皮生长因子 (深圳市华生元基因工程)(Recombinant Human Epidermal Growth Factor Derivative For External Use,Liquid(Shenzhen Watsin Genetech Ltd.))

概要

基本信息

药物类型

生长因子

别名

GeneTime、Recombinant Human Epidermal Growth Factor Derivative、Recombinant epidermal growth factor

+ [3]

靶点

EGFR

作用机制

EGFR拮抗剂(表皮生长因子受体erbB1拮抗剂)

治疗领域

其他疾病

在研适应症

创伤和损伤

非在研适应症-

原研机构

深圳市华生元基因工程发展有限公司

在研机构

深圳市华生元基因工程发展有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (2001-01-01),

创伤和损伤

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

2

项与重组人表皮生长因子 (深圳市华生元基因工程) 相关的临床试验

ChiCTR2000032874 / Recruiting临床4期IIT

To investigate an open, randomized controlled clinical trial of recombinant human epidermal growth factor compound enema for the prevention and treatment of radiation proctitis caused by radical radiotherapy of cervical cancer

开始日期2020-05-18

申办/合作机构-

ChiCTR2000032841 / Recruiting临床4期IIT

To investigate an open, randomized controlled clinical trial of recombinant human epidermal growth factor compound enema solution for the prevention and treatment of radiation proctitis induced by adjuvant radiotherapy for cervical cancer

开始日期2020-05-18

申办/合作机构-

100 项与重组人表皮生长因子 (深圳市华生元基因工程) 相关的临床结果

登录后查看更多信息

100 项与重组人表皮生长因子 (深圳市华生元基因工程) 相关的转化医学

登录后查看更多信息

100 项与重组人表皮生长因子 (深圳市华生元基因工程) 相关的专利（医药）

登录后查看更多信息

20

项与重组人表皮生长因子 (深圳市华生元基因工程) 相关的文献（医药）

2023-04-29·Acta odontologica latinoamericana : AOL

Update on the treatment of chemotherapy and radiotherapy-induced buccal mucositis: a systematic review.

Review

作者: Santander, Javiera ; Wen, Schilin ; Conteras, Gonzalo ; Brito, Leonardo

Oral mucositis (OM) is a frequent complication in cancer patients who are undergoing chemotherapy or radiotherapy. It manifests as an inflammation of the oral mucosa, sometimes provoking severe consequences such as eating limitations, difficulty in speaking, and possibly superinfection.AimThe aim of this review was to update the evidence published during the last five years on the treatment of oral mucositis induced by radiotherapy and/or chemotherapy in patients with cancer.Materials and MethodA search was conducted in Pubmed, Scielo and Scopus, using the search terms mucositis, stomatitis, therapy, treatment, oral cancer, oral squamous cell carcinoma, head and neck cancer and head and neck carcinoma, with Mesh terms and free terms, from 2017 to January 2023. The systematic review was conducted in accordance with the PRISMA guidelines.ResultsA total 287 articles were retrieved, of which 86 were selected by title and abstract, and 18 were included after full-text analysis. The most frequently assessed variables were OM severity, pain intensity and healing time. Treatment types were diverse, and included drugs, mouthwashes, medicines based on plant extracts, cryotherapy and low-intensity laser therapies.ConclusionDentoxol mouthwashes, Plantago major extract, thyme honey extract, zinc oxide paste, vitamin B complex combined with GeneTime, and the consumption of L-glutamine are effective in diminishing the severity of OM. Pain intensity was lower with doxepin mouthwashes and diphenhydramine-lidocaine-antacid mouthwashes.

2022-03-01·Journal of the College of Physicians and Surgeons Pakistan4区 · 医学

Intralesional Epidermal Growth Factor for Diabetic Foot Ulcers

4区 · 医学

Article

作者: Ilkeli, Ekin ; Duzgun, Ali Cemal ; Kanko, Muhip ; Arabaci, Hakan ; Uysal, Ayhan ; Goktas Demircan, Fethiye Berna

OBJECTIVETo determine the role of the intralesional recombinant epidermal growth factor (rEGF) in the healing and prevention of extremity amputation in advanced diabetic foot ulcer patients.STUDY DESIGNObservational study.PLACE AND DURATION OF STUDYDepartment of Cardiovascular Surgery, Duzce State Hospital, Duzce, Turkey, between November 2018 and September 2019.METHODOLOGYA total of 58 patients with diabetic foot ulcers that were treated at the study place were enrolled. The lesions were graded with Wagner Classification System. EGF (75 microg of Heberprot-P) vials were stored at +4°C and cold-chain requirements were followed. EGF 5 mL was dissolved with 0.09% saline solution; and 0.5-1 ml of the solution was injected into the tissues and edge of the lesions regularly. The data was evaluated at the end of two years of the treatment period. The primary objective was wound healing, formation of granulation tissue; and the secondary objective was the prevention of lower extremity amputation.RESULTSDiabetic foot ulcers wound healing was achieved in 93.1% (n=54) of patients with the formation of granulation tissue. The complete recovery was observed in 94.1% (n=32) of the patients who had Grade III and IV lesions. Lower extremity amputation was performed in two (3.4%) subjects. The lesions of two patients required flap surgery. The most common adverse events were tremor and syncope.CONCLUSIONRecombinant epidermal growth factor is highly effective for the treatment of diabetic foot ulcers and prevention of extremity amputation. Intralesional rEGf provides efficient and safe wound healing/closure in patients with diabetic foot ulcers. Key Words: Amputation, Epidermal growth factor, Diabetic foot, Wound healing.

2021-10-01·Cytotechnology4区 · 生物学

Development of a modified serum-free medium for Vero cell cultures: effects of protein hydrolysates, l-glutamine and SITE liquid media supplement on cell growth

4区 · 生物学

Article

作者: Posung, Manoch ; Promkhatkaew, Duanthanorm ; Borg, Jörgen ; Tongta, Anan

Vero cells have been widely used in the viral vaccine production due to the recommendation of the World Health Organization regarding its safety and non-tumorigenicity. The aim of this study was to describe the development a modified serum-free medium for Vero cell cultures. Two protein hydrolysates (Bacto™ soytone and Bacto™ yeast extract), vitamin C, vitamin B12, SITE liquid media supplement, and recombinant human epidermal growth factor (rEGF) were investigated as serum substitutes. A sequential experiment of fractional factorial and central composite design was applied. A modified serum-free medium obtained (named as SFM01-M) was verified. Contrary to P0, the cell yields obtained at P1, P2, and P3 decreased continuously during the verification experiments indicating that Vero cells could not adapt to SFM01-M as expected according to the empirical mathematical model. To improve cell growth after P0, protein hydrolysates, l-glutamine, and SITE liquid media supplement were further investigated. The results showed that cell yields gradually decreased from P1 to P3 when a fixed concentration of Bacto™ yeast extract (7.0 g/L) combined with various concentrations of Bacto™ soytone (0.1-7.0 g/L) in SFM01-M were used. Similarly, cell yields also gradually decreased from P1 to P3 when a fixed concentration of Bacto™ soytone (7.0 g/L) combined with various concentrations of Bacto™ yeast extract (0.1-7.0 g/L) in SFM01-M were used. However, the combination of Bacto™ soytone at 0.1 g/L and Bacto™ yeast extract at 7.0 g/L or Bacto™ soytone at 7.0 g/L and Bacto™ yeast extract at 0.1 g/L in SFM01-M could give the maximum cell yield at P3 when compared with other combinations. In addition, the addition of SITE liquid media supplement (0.1-2.0% v/v) in SFM01-M in which the concentrations of Bacto™ soytone, Bacto™ yeast extract, and l-glutamine were fixed at 0.1 g/L, 0.1 g/L, and 4.0 mM, respectively, the results showed that the cell yields obtained at P3 were not significantly different. From this study, the optimum concentrations of SFM01-M components were as follows: Bacto™ soytone (0.1 g/L), Bacto™ yeast extract (0.1 g/L), vitamin C (9.719 mg/L), vitamin B12 (0.1725 mg/L), SITE liquid media supplement (0.1-2.0% v/v), rEGF (0.05756 mg/L), l-glutamine (4.0 mM), MEM non-essential amino acids (1.0% v/v), sodium pyruvate (1.0 mM), MEM (9.4 g/L), and sodium hydrogen carbonate (2.2 g/L). However, to evaluate SFM01-M in the long-term subculture of Vero cells, the efficiency of SFM01-M will be further investigated.

100 项与重组人表皮生长因子 (深圳市华生元基因工程) 相关的药物交易

登录后查看更多信息